NCT07090668
Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
At risk: Primary completion moved at least 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 18 words
- Primary and study completion pushed from Jul 2026 to Jan 2027
- Secondary endpoints: details revised at 4 of 5 entries
- Site details revised
- Notable Eligibility criteria revised
- Interventions: taVNS device (Device) to tAN device (Device)
- Study description expanded, about 14 words
- Study title shortened, about 1 word
- Minor Start date changed from estimate of Aug 2025 to Aug 12, 2025v3
- Minor Start date: Jul 2025 to Aug 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Feasibility: Completion Rate
Timeframe: Through study completion (an average of 3-7 days)
Stimulation tolerability
Timeframe: Baseline, everyday throughout the study (an average of 3-7 days)
Acceptability of intervention
Timeframe: Baseline, everyday throughout the study (an average of 3-7 days)
Secondary (5)
Wong-Baker FACES
Functional Status Scale(FSS)
Change in Interleukin 6 (IL-6) levels
Change in MCP-1
Change in Tumor necrosis factor (TNF-α)
Arms and interventions
Controls (Same participant but past data)No intervention
Participants will serve as their own controls. Using chart review, we will collect data from each participant's previous admission for a pain crisis during which they did not receive tAN treatment and compare it to their current admission, during which they are being treated with tAN
tAN groupExperimental
Subjects admitted to CHOA with SCD pain crisis.
Devices: tAN device
Sites
1 site in 1 country
- Children's Hospital of Atlanta: EagelstonAtlanta, Georgia, United States